Celcuity (CELC) Accumulated Expenses (2016 - 2025)
Celcuity's (CELC) quarterly Accumulated Expenses came in at $27.3 million in Q3 2025, up 60.7% YoY from $17.0 million in Q3 2024, and down 4.77% on a QoQ basis from $28.6 million in Q2 2025.
Celcuity (CELC) Accumulated Expenses (2016 - 2025) Analysis & Trends
Celcuity (CELC) has 10 years of Accumulated Expenses data on file, last reported at $27.3 million in Q3 2025.
- Quarterly Accumulated Expenses rose 60.7% year-over-year to $27.3 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $27.3 million (up 60.7% YoY) and the FY2024 annual result came in at $22.2 million, up 38486.64% from the prior year.
- Accumulated Expenses fell to $27.3 million in Q3 2025, from $28.6 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $28.6 million in Q2 2025 to a low of $57494.0 in Q4 2023.
- A 5-year average of $8.7 million and a median of $3.3 million in 2022 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2023 — Accumulated Expenses slumped 93.81% — and 2024, when it soared 38486.64%.
- Tracing CELC's Accumulated Expenses over 5 years: stood at $438477.0 in 2021, then surged by 111.92% to $929216.0 in 2022, then tumbled by 93.81% to $57494.0 in 2023, then soared by 38486.64% to $22.2 million in 2024, then rose by 22.96% to $27.3 million in 2025.
- The last three Accumulated Expenses figures came in at $27.3 million (Q3 2025), $28.6 million (Q2 2025), and $22.8 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Celcuity | 4.50 Bn | 4.50 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 27.28 Mn |
| Jun 30, 2025 | 28.64 Mn |
| Mar 31, 2025 | 22.82 Mn |
| Dec 31, 2024 | 22.19 Mn |
| Sep 30, 2024 | 16.97 Mn |
| Jun 30, 2024 | 13.15 Mn |
| Mar 31, 2024 | 11.24 Mn |
| Dec 31, 2023 | 57,494.00 |
| Sep 30, 2023 | 6.89 Mn |
| Jun 30, 2023 | 3.87 Mn |
| Mar 31, 2023 | 3.04 Mn |
| Dec 31, 2022 | 929,216.00 |
| Sep 30, 2022 | 3.28 Mn |
| Jun 30, 2022 | 1.68 Mn |
| Mar 31, 2022 | 1.22 Mn |
| Dec 31, 2021 | 438,477.00 |
| Sep 30, 2021 | 879,851.00 |
| Jun 30, 2021 | 729,672.00 |
| Mar 31, 2021 | 660,849.00 |
| Dec 31, 2020 | 137,020.00 |